Anzeige
Mehr »
Montag, 30.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
167 Leser
Artikel bewerten:
(1)

Qiming Venture Partners' Portfolio Company Unisound Successfully Lists on the Hong Kong Stock Exchange

SHANGHAI, June 30, 2025 /PRNewswire/ -- On June 30th, Beijing time, Unisound, a pioneer in the industrialization of AI technologies in China and a portfolio company of Qiming Venture Partners, has successfully debuted on the Hong Kong Stock Exchange. Unisound (SEHK:9678) was issued at HK$205.00 per share, with a market capitalization of HK$14.545 billion.

Qiming Venture Partners has been a long-standing investor in Unisound, first participating in the company's Series A funding round in 2013. Over the past decade, Qiming has continued to support Unisound through its Series B and D1 rounds.

Founded in 2012, Unisound is an AI company specializing in the conversational AI products and solutions for daily life and healthcare-related applications in China. Its business centers on empowering customers, including insurance providers and over 100 hospitals, with user-centric AI solutions that enhance operational efficiency and support better decision-making.

Leveraging a solid infrastructure, Unisound has advanced its R&D and productization capabilities. In 2019, the company launched UniCore, its first BERT-based large language model, which functioned as the initial core algorithm model of its central technology platform, UniBrain. In 2023, Unisound introduced UniGPT, UniBrain's new core algorithm model-a 60-billion-parameter large language model with generative multilingual and multimodal capabilities that enables human-machine interaction through dynamic reasoning and cross-modal data processing.

"This IPO represents strong market recognition of China's AI technology commercialization and a meaningful step forward in the industrialization of AI technology," said Dr. Huang Wei, Co-Founder and CEO of Unisound. "We will continue to invest in core AI infrastructure and model development, cultivate talent, and strategically expand globally to bring our advanced technologies and products to the international markets."

"As an early investor in Unisound, we are delighted to have witnessed its remarkable leap from technological exploration to a successful IPO," said Duane Kuang, Founding Managing Partner of Qiming Venture Partners. "Unisound's listing marks a new chapter for the company and highlights the significant progress in the industrialization of AI in China. We look forward to seeing Unisound continue to push the boundaries of innovation, accelerate talent acquisition and development, and showcase the strength of Chinese AI companies. At Qiming, we remain committed to supporting companies like Unisound that combine deep technological expertise with strong commercial vision and long-term growth potential."

About Qiming Venture Partners

Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.

Since our debut, we have backed over 580 fast-growing and innovative companies. Over 210 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 80 portfolio companies that have achieved unicorn or super unicorn status.

Many of our portfolio companies are today's most influential firms in their respective sectors, including Xiaomi, Meituan, Bilibili, Zhihu, Roborock, UBTech, WeRide, Insta360, Gan & Lee Pharmaceuticals, Tigermed, Zai Lab, CanSino Biologics, Schrödinger, APT Medical, Sanyou Medical, AmoyDx, Berry Genomics, SinocellTech, Yuanxin Technology, Insilico Medicine, Medilink Therapeutics, LaNova Medicines, Zhipu, StepFun, among many others.

Cision View original content:https://www.prnewswire.co.uk/news-releases/qiming-venture-partners-portfolio-company-unisound-successfully-lists-on-the-hong-kong-stock-exchange-302494272.html

© 2025 PR Newswire
Die USA haben fertig! 5 Aktien für den China-Boom
Die Finanzwelt ist im Umbruch! Nach Jahren der Dominanz erschüttert Donald Trumps erratische Wirtschaftspolitik das Fundament des amerikanischen Kapitalismus. Handelskriege, Rekordzölle und politische Isolation haben eine Kapitalflucht historischen Ausmaßes ausgelöst.

Milliarden strömen aus den USA – und suchen neue, lukrative Ziele. Und genau hier kommt China ins Spiel. Trotz aller Spannungen wächst die chinesische Wirtschaft dynamisch weiter, Innovation und Digitalisierung treiben die Märkte an.

Im kostenlosen Spezialreport stellen wir Ihnen 5 Aktien aus China vor, die vom US-Niedergang profitieren und das Potenzial haben, den Markt regelrecht zu überflügeln. Wer jetzt klug investiert, sichert sich den Zugang zu den neuen Wachstums-Champions von morgen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche 5 Aktien die Konkurrenz aus den USA outperformen dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.